Test Menu
Respiratory Infections
Respiratory Panel:
Bocavirus
Coronavirus 229
Coronavirus OC43 Coronavirus HKU1
Enterovirus
Human adenovirus
Human parechovirus
Human rhinovirus
Influenza A
Influenza B
Metapneumovirus A/B
Parainfluenza 1
Parainfluenza 2
Parainfluenza 3
Parainfluenza 4
RSV A/B Bordetella spp.
Chlamydophila pneumoniae
Haemophilus influenzae
Haemophilus influenzae B
Klebsiella pneumoniae
Legionella pneumophila/longbeachae
Moraxella catarrhalis
Mycoplasma pneumoniae
Salmonella spp.
Staphylococcus aureus
Streptococcus pneumoniae
COVID Panel: SARs-CoV-2
Strep Panel: Streptococcus dysgalactiae
Streptococcus pyogenes
Gastrointestinal Infections
GI Panel:
Salmonella spp.
Shigella spp./EIEC (sonnei, boydii, dysenteriae, flexneri)
STEC (Shigatoxin producing Escherica coli)
ETEC (Enterotoxogenic Escherichia coli)
EPEC (Enteropathogenic Escherichia coli)
EAEC (Enteroaggregative Eschericia coli) Campylobacter spp.
Clostridium difficile Tox NAAT
Yersinia enterocolitica Vibrio spp. (cholerae, parahaemolyticus, vulnificus)
Aeromonas spp. (caviae, hydrophila, veronii)
Plesiomonas shigelloides
Adenovirus 40/41
Norovirus GI/GII
Rotavirus A
Sapovirus
Astrovirus
Giardia lamblia Entamoeba histolytica
Cryptosporidium
Dientamoeba fragilis Cyclospora
Blastocystis hominis
H Pylori Test: Helicobacter pylori
Clostridium difficile NAAT: Clostridium difficile
C. difficile GDH & Toxin A/B Antigen*: Clostridium difficile GDH
Clostridium difficile Toxin A/B
*Reflex test to NAAT when GDH and Toxin results differ
Fecal Occult Blood
Fecal White Blood Cells
Quantitative Fecal Calprotectin
Quantitative Fecal Pancreatic Elastase
Other Infections
Sexual Health Panel:
Herpes simplex virus type 1
Herpes simplex virus type 2
Neisseria gonorrhoeae
Gardnerella vaginalis
Trichomonas vaginalis
Haemophilus ducreyi
Mycoplasma genitalium
Mycoplasma hominis
Ureaplasma urealyticum
Treponema pallidium
Lymphogranuloma Types 1, 2, & 3
Chlamydia trachomatis
Candida albicans
Candida glabrata
Candida tropicalis
Candida parapsilosis
Candida krusei
Candida auris
HSV/VZV Panel:
Herpes simplex virus type 1
Herpes simplex virus type 2
Varicella-zoster virus
UTI/Wound Panel:
Acinetobacter baumannii
Candida albicans
Candida glabrata
Candida tropicalis
Candida parapsilosis
Candida krusei
Citrobacter freundii
Citrobacter koseri
Corynebacterium urealyticum
Enterobacter cloacae complex
Enterococcus faecalis
Enterococcus faecium
Escherichia coli
Klebsiella aerogenes
Klebsiella oxytoca
Klebsiella pneumoniae
Morganella morganii
Proteus mirabilis
Proteus vulgaris
Providencia stuartii
Pseudomonas aeruginosa
Serratia marcescens
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus saprophyticus
Streptococcus agalactiae
Streptococcus anginosis
Drug Resistance:
Beta-lactam (CTX-M, NDM, VIM)
Carbapenem (KPC, OXA-48, IMP)
Vancomycin (vanA, vanB)
Sulfonimide (sul)
Trimethoprim (dfr)
Methicillin (mecA, MecB/C)
Nitrofurantoin (nfs)
*Reflex test to Drug Resistance for positive UTI/Wound results. Negative wound panel results and negative UTI panel with positive UA results will be sent out for culture.
Non-Variola Orthopoxvirus Panel:
Non-Variola Orthopoxvirus
Monkeypox virus
In Sickness and in Health
Why partnering with Magnolia is good for your practice
The Magnolia Model
Symptoms & Pathogen Identification
STEP ONE
Whether your patient presents with peptic ulcers or pharyngitis, Magnolia has a test with both clinician and patient in mind. Unsure what to order? Use our ICD-10 checker here.
Order
STEP TWO
Simply fax a requisition form or submit an order directly through our portal. A courier will be dispatched upon receipt of a requisition for pick-up no later than COB that day.
Detection
STEP THREE
Magnolia uses all Polymerase chain reaction (PCR) technology to detect over 60 infections spanning across 5 different pathogenic classes. All results are available within 24 hours of receipt of a specimen (same-day results available in Texas).
Treatment
STEP FOUR
Prescribe precise and personalized treatment that’s evidence-based from a definitive diagnosis.
Monitoring
STEP FIVE
Confirm eradication through repeat testing when indicated.
Answers before antibiotics
Don’t just take our word for it, we have the research to back it up.
Show me the research >
By rapidly identifying the exact source of infection, our comprehensive panels:
1. Reduce unnecessary antibiotic prescribing
2. Reduce diagnostic and treatment delays
3. Improve quality of care and infection control
4. Improve patient outcomes
5. Reduce the overall economic burden of these infections
The threat of antibiotic-resistance
50-75% of antibiotics prescribed for respiratory infections in the outpatient and ambulatory setting are unnecessary. (5,6)
As a result, bacteria is becoming resistant to antibiotics and prevents antibiotics from working properly when antibiotics are necessary. (7)
Antibiotic-resistant bacteria have become a critical threat to healthcare and are projected to kill more people worldwide than cancer by 2050. (8)
Rapid detection of infections is crucial for the appropriate use of antibiotics and overall cost savings to the healthcare system. (9)
Not only does a rapid infection panel contribute to antibiotic stewardship, it also improves patient outcomes. (10)
Research Sources
1. Poehling KA e. The underrecognized burden of influenza in young children. - PubMed - NCBI. Ncbinlmnihgov. 2015. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16822994. Accessed October 26, 2015.
2. Scallan E., Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson M-A, Roy SL, Jones JL, and Griffin PM. Foodborne illness acquired in the United States—major pathogens. Emerg Infect Dis. 2011; 17:7-15
3. Centers for Disease Control (Internet). About the flu; influenza: the disease. 2004. Cited 2015 October. Available from: http://www.cdc.gov/flu/about/disease.htm Accessed October 2015.
4. U.S. Dept. of Health and Human Services. National Statistics on Intestinal Infections, 2010.
5. CDC Recommends All Nursing Homes Implement Core Elements to Improve Antibiotic Use. Centers for Disease Control and Prevention. http://www.cdc.gov/media/releases/2015/p0915-nursing-home-antibiotics.html. Published September 15, 2015. Accessed September 14, 2016.
6. CDC: 1 in 3 antibiotic prescriptions unnecessary. Centers for Disease Control and Prevention. http://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html. Published May 1, 2016. Accessed September 14, 2016.
7. What is Antibiotic Resistance and Why is it a problem? Alliance For The Prudent Use of Antibiotics. http://emerald.tufts.edu/med/apua/about_issue/antibiotic_res.shtml. Accessed August 8, 2016.
8. Taylor, Jirka, Marco Hafner, Erez Yerushalmi, Richard Smith, Jacopo Bellasio, Raffaele Vardavas, Teresa Bienkowska-Gibbs and Jennifer Rubin. Estimating the economic costs of antimicrobial resistance: Model and Results. Santa Monica, CA: RAND Corporation, 2014. http://www.rand.org/pubs/research_reports/RR911.html.
9. Sidlak M. Clinical Microbiology Costs for Routine Stool Specimen work-up versus Multiplex PCR GI Panel. 2015.
10. Pettit N, et al. Comparison of Turnaround Time (TAT) and Time to Oseltamivir Discontinuation between Two Respiratory Viral Panel Testing (RVP) Methodologies. 2015.
